Medium-Chain Triglycerides

Medium-chain triglycerides (MCTs) are esters of glycerol with medium-chain saturated fatty acids — specifically those with 6 to 12 carbon atoms. They occupy a unique absorption and metabolism niche distinct from long-chain triglycerides (LCTs, C14+) that comprise the majority of dietary fat, making them useful in specific clinical nutrition contexts.

Component fatty acids

The four fatty acids encompassed by the MCT designation are caproic acid (C6:0, 4% of coconut oil), caprylic acid (C8:0, 7%), capric acid (C10:0, 7%), and lauric acid (C12:0, 49%). Commercial MCT oil is typically manufactured from coconut or palm kernel oil by fractional distillation, yielding a blend heavily enriched in C8 and C10 (since lauric acid C12 is often excluded because it behaves more like an LCT in absorption). Coconut oil as a whole food is approximately 50% lauric acid, with only ~15% of its fatty acids in the strict C6-C10 MCT range.

Absorption and metabolism

The distinctive feature of MCTs is absorption via the portal circulation directly to the liver, bypassing the chylomicron-lymphatic pathway used by long-chain triglycerides. Medium-chain fatty acids are hydrolyzed in the intestinal lumen by pancreatic and gastric lipases, absorbed intact by enterocytes, and exported into portal blood bound to albumin rather than packaged in chylomicrons. In the liver, they are rapidly activated and transported into mitochondria without requiring carnitine — a major kinetic advantage — and beta-oxidized to acetyl-CoA, much of which is directed into ketogenesis rather than TCA cycle entry.

Ketogenic effect

MCT oil raises blood BHB concentration within 60-90 minutes of ingestion in dose-dependent fashion, even in the presence of dietary carbohydrate that would normally suppress ketogenesis. A typical dose of 20-30 g MCT oil can produce acute BHB elevations of 0.3-0.8 mmol/L. This enables "modified" or "MCT-based" ketogenic diets used in pediatric epilepsy with slightly higher carbohydrate allowances than classical 4:1 ratio ketogenic diets.

Clinical applications

Established clinical uses of MCT: (1) fat malabsorption syndromes — pancreatic insufficiency, cystic fibrosis, short bowel syndrome, chylothorax — where MCTs provide fat calories without requiring intact bile acid and pancreatic lipase function; (2) MCT-based ketogenic diets in pediatric epilepsy; (3) parenteral nutrition formulations blending MCT with LCT for hepatic-sparing effect; (4) investigational cognitive-aging interventions particularly in mild Alzheimer's disease, where exogenous MCT-derived ketones may compensate for regional cerebral glucose hypometabolism.

Side effects and limitations

MCT oil commonly causes osmotic diarrhea and gastrointestinal discomfort at single doses above 20-30 g, limiting practical dosing. Tolerance improves with gradual titration. Because MCTs are efficiently oxidized rather than stored, they are sometimes marketed as "thermogenic" or metabolically advantageous for weight loss; clinical trial evidence for meaningful weight loss benefit beyond isocaloric substitution is modest at best.

Caloric density

MCTs provide approximately 8.3 kcal/g, slightly less than LCTs (9.0 kcal/g), reflecting their somewhat incomplete oxidation and partial diversion to ketones. This distinction matters for precise dietary calculation in clinical enteral nutrition; standard nutrition tracking treats all fats as 9 kcal/g, which slightly over-counts MCT-heavy intake.